MA40386A - Procédé de préparation de cabozantinib marqué au fluor-18 et d'analogues de celui-ci - Google Patents

Procédé de préparation de cabozantinib marqué au fluor-18 et d'analogues de celui-ci

Info

Publication number
MA40386A
MA40386A MA040386A MA40386A MA40386A MA 40386 A MA40386 A MA 40386A MA 040386 A MA040386 A MA 040386A MA 40386 A MA40386 A MA 40386A MA 40386 A MA40386 A MA 40386A
Authority
MA
Morocco
Prior art keywords
analogs
cabozantinib
preparing fluorine
labeled
preparing
Prior art date
Application number
MA040386A
Other languages
English (en)
Inventor
Patrick L Chow
David J Donnelly
Benjamin J Henley
Wei Xu
Original Assignee
Exelixis Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Exelixis Inc filed Critical Exelixis Inc
Publication of MA40386A publication Critical patent/MA40386A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/22—Oxygen atoms attached in position 2 or 4
    • C07D215/233—Oxygen atoms attached in position 2 or 4 only one oxygen atom which is attached in position 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/22—Oxygen atoms attached in position 2 or 4

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Cette invention concerne un procédé de préparation de cabozantinib ([4- (6,7-diméthoxy-quinolin-4-yloxy)phénylo]amide-(4-fluoro-phényl)amide) d'acide cyclopropane-1,1-dicarboxylique) et de cabozantinib marqué au
MA040386A 2014-07-31 2015-07-31 Procédé de préparation de cabozantinib marqué au fluor-18 et d'analogues de celui-ci MA40386A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201462031471P 2014-07-31 2014-07-31

Publications (1)

Publication Number Publication Date
MA40386A true MA40386A (fr) 2016-02-04

Family

ID=54072944

Family Applications (1)

Application Number Title Priority Date Filing Date
MA040386A MA40386A (fr) 2014-07-31 2015-07-31 Procédé de préparation de cabozantinib marqué au fluor-18 et d'analogues de celui-ci

Country Status (9)

Country Link
US (2) US11124481B2 (fr)
EP (1) EP3174854B1 (fr)
JP (2) JP6789923B2 (fr)
CN (1) CN106715397B (fr)
CA (1) CA2956810C (fr)
EA (1) EA033834B1 (fr)
ES (1) ES2929888T3 (fr)
MA (1) MA40386A (fr)
WO (1) WO2016019285A1 (fr)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2907334C (fr) * 2013-03-15 2021-12-07 Exelixis, Inc. Metabolites de n-(4-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}phenyl)-n'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide
BR112016018450A2 (pt) 2014-02-14 2018-09-18 Exelixis Inc formas sólidas cristalinas de n-{4-[(6,7-dimetoxiquinolin-4-il)oxi]fenil}-n'-(4-fluorofenil)ciclopropano-1,1-dicarboxamida, processos de preparo e métodos de uso
EP3119476A1 (fr) 2014-03-17 2017-01-25 Exelixis, Inc. Dosage de préparations de cabozantinib
EP3174854B1 (fr) * 2014-07-31 2022-08-24 Exelixis, Inc. Procédé de préparation de cabozantinib marqué au fluor-18 et d'analogues de celui-ci
MX382904B (es) 2014-08-05 2025-03-13 Exelixis Inc Combinaciones de fármacos para tratar mieloma múltiple.
EP3442531A1 (fr) 2016-04-15 2019-02-20 Exelixis, Inc. Procédé de traitement du cancer à cellules rénales à l'aide de n-(4-(6,7-diméthoxyquinolin-4-yloxy) phényl)-n'-(4-fluorophény)cyclopropane-1,1-dicarboxamide, (2s)-hydroxybutanedioate
CN107556238A (zh) * 2016-06-30 2018-01-09 深圳万乐药业有限公司 一种卡博替尼的合成方法
GB201621864D0 (en) 2016-12-21 2017-02-01 Ge Healthcare Ltd Solid phase conditioning
AU2018279834B2 (en) * 2017-06-09 2024-05-23 Exelixis, Inc. Liquid dosage forms to treat cancer
CN109836381A (zh) * 2017-11-29 2019-06-04 连云港恒运药业有限公司 多受体酪氨酸激酶抑制剂及其中间体的制备方法
CN109988107B (zh) * 2017-12-29 2022-01-14 江苏豪森药业集团有限公司 卡博替尼的制备方法
CN117402114A (zh) 2018-01-26 2024-01-16 埃克塞里艾克西斯公司 用于治疗激酶依赖性病症的化合物
TWI831259B (zh) * 2018-06-15 2024-02-01 漢達生技醫藥股份有限公司 包含達沙替尼十二烷基硫酸鹽組合物的膠囊
CN110143917B (zh) * 2019-07-09 2020-03-31 郑州大学第一附属医院 一种卡博替尼代谢物的制备方法
CN110903240A (zh) * 2019-12-12 2020-03-24 上海玉函化工有限公司 一种广谱抗癌药卡博替尼的制备方法
CN115461328B (zh) 2020-04-30 2025-11-07 埃克塞里艾克西斯公司 用于制备激酶抑制剂的方法
TW202346255A (zh) * 2022-01-06 2023-12-01 日商中外製藥股份有限公司 醯胺化合物的製造方法
CN120239695A (zh) * 2022-12-01 2025-07-01 江苏奥赛康药业有限公司 一种制备卡博替尼及其中间体的方法
WO2024163400A1 (fr) * 2023-01-31 2024-08-08 Handa Oncology, Llc Compositions de cabozantinib améliorées et procédés d'utilisation
WO2025115975A1 (fr) * 2023-11-30 2025-06-05 日産化学株式会社 Procédé de production d'un composé amino aromatique

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050030140A1 (en) * 2000-04-03 2005-02-10 Mikael Dahlgren Multiphase induction device
EP2210607B1 (fr) 2003-09-26 2011-08-17 Exelixis Inc. N-[3-fluoro-4-({6-(méthyloxy)-7-[(3-morpholin-4-ylpropyl)oxy]quinolin-4-yl}oxy)phényl]-N'-(4-fluorophényl)cyclopropane-1,1-dicarboxamide pour le traitement du cancer
US7977345B2 (en) 2004-07-02 2011-07-12 Exelixis, Inc. c-MET modulators and method of use
EP1874759A4 (fr) 2005-04-06 2009-07-15 Exelixis Inc Modulateurs c-met modulators et procedes d utilisation
JP2007056777A (ja) 2005-08-25 2007-03-08 Daido Steel Co Ltd 電磁駆動弁
US7790885B2 (en) * 2006-08-31 2010-09-07 Eisai R&D Management Co., Ltd. Process for preparing phenoxypyridine derivatives
PL2101759T3 (pl) 2006-12-14 2019-05-31 Exelixis Inc Sposoby stosowania inhibitorów MEK
UY31800A (es) 2008-05-05 2009-11-10 Smithkline Beckman Corp Metodo de tratamiento de cancer usando un inhibidor de cmet y axl y un inhibidor de erbb
AR075084A1 (es) 2008-09-26 2011-03-09 Smithkline Beecham Corp Metodo de preparacion de quinolinil -oxidifenil - ciclopropanodicarboxamidas e intermediarios correspondientes
JP5486606B2 (ja) 2008-11-13 2014-05-07 エクセリクシス， インク． キノリン誘導体の調製方法
US20130030172A1 (en) 2008-12-04 2013-01-31 Exelixis, Inc. Methods of Preparing Quinoline Derivatives
NZ779754A (en) 2009-01-16 2023-04-28 Exelixis Inc Malate salt of n-(4-{ [6,7-bis(methyloxy)quinolin-4-yl] oxy} phenyl)-n’-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide, and crystalline forms thereof for the treatment of cancer
CN102510855B (zh) 2009-07-17 2015-11-25 埃克塞里艾克西斯公司 N-[3-氟-4-({6-(甲基氧基)-7-[(3-吗啉-4-基丙基)氧基]-喹啉-4-基}氧基)苯基]-n′-(4-氟苯基)环丙烷-1，1-二甲酰胺的晶形
UA108618C2 (uk) 2009-08-07 2015-05-25 Застосування c-met-модуляторів в комбінації з темозоломідом та/або променевою терапією для лікування раку
AU2011224203A1 (en) 2010-03-12 2012-10-04 Exelixis, Inc Hydrated crystalline forms of N-[3-fluoro-4-({6-(methyloxy)-7-[(3-morpholin -4-ylpropyl)oxy]-quinolin-4-yl}oxy)phenyl] -N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide
US20120070368A1 (en) 2010-04-16 2012-03-22 Exelixis, Inc. Methods of Using C-Met Modulators
EA030435B1 (ru) 2010-07-16 2018-08-31 Экселиксис, Инк. ТАБЛЕТКА, СОДЕРЖАЩАЯ МОДУЛЯТОР c-MET В ФОРМЕ КРИСТАЛЛИЧЕСКОЙ L-МАЛАТНОЙ СОЛИ (ВАРИАНТЫ), СПОСОБ ЕЕ ПРОИЗВОДСТВА И СПОСОБ ЛЕЧЕНИЯ ОНКОЛОГИЧЕСКОГО ЗАБОЛЕВАНИЯ С ЕЕ ИСПОЛЬЗОВАНИЕМ
US20140186407A9 (en) 2010-07-16 2014-07-03 Exelixis Inc. C-Met Modulator Pharmaceutical Compositions
MX352926B (es) 2010-09-27 2017-12-14 Exelixis Inc Inhibidores dobles de met y factor de crecimiento endotelial vascular (vegf) para el tratamiento de cancer de prostata resistente a la castracion y metastasis osteoblasticas en los huesos.
JP2013540759A (ja) 2010-09-27 2013-11-07 エクセリクシス， インク． 去勢抵抗性前立腺癌および造骨性転移の治療のためのｍｅｔおよびｖｅｇｆの二元阻害薬
US20140057908A1 (en) 2010-09-27 2014-02-27 Exelixis, Inc. Method of Treating Cancer
WO2012071321A1 (fr) 2010-11-22 2012-05-31 Glaxosmithkline Llc Procédé de traitement du cancer
BR112013020362A2 (pt) 2011-02-10 2018-05-29 Exelixis Inc processos para a preparação de compostos de quinolina, compostos e combinações farmacêuticas que os contem
US20120252840A1 (en) 2011-04-04 2012-10-04 Exelixis, Inc. Method of Treating Cancer
MX2013012695A (es) 2011-05-02 2014-03-27 Exelixis Inc Metodo para el tratamiento del cancer y el dolor por cancer de hueso.
TW201306842A (zh) 2011-06-15 2013-02-16 Exelixis Inc 使用ｐｉ３ｋ／ｍｔｏｒ吡啶並嘧啶酮抑制劑及苯達莫司汀及／或利妥昔單抗治療惡性血液疾病之組合療法
EP2758057B1 (fr) 2011-09-22 2017-05-31 Exelixis, Inc. Méthode de traitement de l'ostéoporose
CN104395284A (zh) 2011-10-20 2015-03-04 埃克塞里艾克西斯公司 制备喹啉衍生物的方法
IN2014CN04067A (fr) 2011-11-08 2015-10-23 Exelixis Inc
WO2013166296A1 (fr) 2012-05-02 2013-11-07 Exelixis, Inc. Double modulateur met-vegf pour traiter des métastases osseuses ostéolytiques
JP6513567B2 (ja) 2012-09-07 2019-05-15 エクセリクシス， インク． 肺腺癌の治療で使用するためのｍｅｔ、ｖｅｇｆｒ、およびｒｅｔの阻害剤
CN103664776B (zh) * 2012-09-26 2016-05-04 正大天晴药业集团股份有限公司 一种酪氨酸激酶抑制剂及其中间体的制备方法
US20140221372A1 (en) 2013-02-06 2014-08-07 GlaxoSmithKline Intellectual Property (NO 2.) Limited Method of administration and treatment
CA2907334C (fr) 2013-03-15 2021-12-07 Exelixis, Inc. Metabolites de n-(4-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}phenyl)-n'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide
US11564915B2 (en) * 2013-04-04 2023-01-31 Exelixis, Inc. Cabozantinib dosage form and use in the treatment of cancer
WO2014165779A1 (fr) 2013-04-04 2014-10-09 Exelixis, Inc. Associations médicamenteuses pour traiter un cancer
BR112016018450A2 (pt) 2014-02-14 2018-09-18 Exelixis Inc formas sólidas cristalinas de n-{4-[(6,7-dimetoxiquinolin-4-il)oxi]fenil}-n'-(4-fluorofenil)ciclopropano-1,1-dicarboxamida, processos de preparo e métodos de uso
EP3119476A1 (fr) * 2014-03-17 2017-01-25 Exelixis, Inc. Dosage de préparations de cabozantinib
UA121655C2 (uk) 2014-04-25 2020-07-10 Екселіксіс, Інк. Спосіб лікування аденокарциноми легень
EP3174854B1 (fr) * 2014-07-31 2022-08-24 Exelixis, Inc. Procédé de préparation de cabozantinib marqué au fluor-18 et d'analogues de celui-ci
MX382904B (es) 2014-08-05 2025-03-13 Exelixis Inc Combinaciones de fármacos para tratar mieloma múltiple.
TW201625243A (zh) 2014-10-14 2016-07-16 艾克塞里克斯公司 用於治療黑素瘤之藥物組合
CN107531626B (zh) 2015-04-07 2020-08-11 尤尼吉可株式会社 双酰亚胺二羧酸的制造方法
US11198731B2 (en) 2017-01-20 2021-12-14 Exelixis, Inc. Combinations of cabozantinib and atezolizumab to treat cancer

Also Published As

Publication number Publication date
CA2956810A1 (fr) 2016-02-04
CA2956810C (fr) 2022-10-04
WO2016019285A1 (fr) 2016-02-04
EA201790286A1 (ru) 2017-06-30
ES2929888T3 (es) 2022-12-02
US20170217896A1 (en) 2017-08-03
EP3174854B1 (fr) 2022-08-24
JP2020186261A (ja) 2020-11-19
JP2017523195A (ja) 2017-08-17
EP3174854A1 (fr) 2017-06-07
JP6789923B2 (ja) 2020-11-25
CN106715397A (zh) 2017-05-24
EA033834B1 (ru) 2019-11-29
US11124481B2 (en) 2021-09-21
CN106715397B (zh) 2021-07-23
US20220194902A1 (en) 2022-06-23

Similar Documents

Publication Publication Date Title
MA40386A (fr) Procédé de préparation de cabozantinib marqué au fluor-18 et d'analogues de celui-ci
IN2014CH00247A (fr)
PH12016501966A1 (en) Compounds and compositions as toll-like receptor 7 agonists
GEP20196974B (en) A novel crystalline form of a benzimidazole derivative and a preparation method thereof
PT3142785T (pt) Processo para a produção de alcenóis e sua utilização para a produção de 1,3-butadieno
PH12020550871A1 (en) Process for the preparation of opicapone and intermediates thereof
WO2014125506A3 (fr) Procédé de préparation d'ivacaftor et de ses intermédiaires
PH12016502229A1 (en) Process for preparing phosphorus-containing cyanohydrins
IN2013MU00848A (fr)
EP3122342A4 (fr) Procédé pour la préparation d'un amide de n-acétylcystéine
EP3265083A4 (fr) Analogues de depsipeptide d'urée substitués à utiliser en tant qu'activateurs de l'endopeptidase clpp
IN2013CH04906A (fr)
PL3073404T3 (pl) Sposób identyfikacji sygnatury interakcji użytkownika
PH12016501326A1 (en) (s)-3'-methyl-abscisic acid and esters thereof
ZA201803105B (en) Industrial process for the preparation of (5s,10s)-10-benzyl-16-methyl-11,14,18-trioxo-15,17,19-trioxa-2,7,8-trithia-12-azahenicosan-5-aminium (e)-3-carboxyacrylate salt
PH12016502592A1 (en) 3'-substituted-abscisic acid derivatives
EP3130593A4 (fr) Dérivé d'acide phosphonique de phénanthroline et son procédé de préparation et d'utilisation
MX382629B (es) Preparación de 3-fluoropropil-nor-beta-cit radioyodado.
MX384260B (es) Proceso para la preparacion de 3,7-dimetilnonan-1-ol.
MA40444A (fr) Procédé de préparation de formulations de poudre sèche
IL250260A0 (en) Process for preparing 4,5,6-trichloropicolinic acid
GEP20196944B (en) Process for preparing the inhalation formulations
IN2013CH05865A (fr)
MA40443A (fr) Nouveau procédé de préparation de formulations de poudre sèche
IN2014MU01191A (fr)